178 related articles for article (PubMed ID: 37188126)
1.
Khonrak T; Watcharadetwittaya S; Chamgramol Y; Intarawichian P; Deenonpoe R
Pathol Oncol Res; 2023; 29():1611138. PubMed ID: 37188126
[No Abstract] [Full Text] [Related]
2. An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.
Zhang T; Lu Y; Ye Q; Zhang M; Zheng L; Yin X; Gavine P; Sun Z; Ji Q; Zhu G; Su X
Genes Chromosomes Cancer; 2015 Mar; 54(3):168-76. PubMed ID: 25407564
[TBL] [Abstract][Full Text] [Related]
3. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
4. RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.
Khan MS; Qadri Q; Makhdoomi MJ; Wani MA; Malik AA; Niyaz M; Masoodi SR; Andrabi KI; Ahmad R; Mudassar S
Pathol Oncol Res; 2020 Jan; 26(1):507-513. PubMed ID: 30467698
[TBL] [Abstract][Full Text] [Related]
5. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
[TBL] [Abstract][Full Text] [Related]
6. [
Zhang X; Su X; Chen WC; Li Y; Yang ZY; Deng WZ; Deng TC; Yang AK
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 52(6):435-439. PubMed ID: 28635216
[No Abstract] [Full Text] [Related]
7. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
8.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
9. Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.
Ferraz C; Rehfeld C; Krogdahl A; Precht Jensen EM; Bösenberg E; Narz F; Hegedüs L; Paschke R; Eszlinger M
Thyroid; 2012 Oct; 22(10):1025-30. PubMed ID: 23025542
[TBL] [Abstract][Full Text] [Related]
10. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.
Staubitz JI; Musholt TJ; Schad A; Springer E; Lang H; Rajalingam K; Roth W; Hartmann N
Cancer Genet; 2019 Oct; 238():10-17. PubMed ID: 31425920
[TBL] [Abstract][Full Text] [Related]
11. Pitfalls in RET Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma.
Liu Y; Wu S; Zhou L; Guo Y; Zeng X
J Clin Endocrinol Metab; 2021 Mar; 106(4):1129-1138. PubMed ID: 33382428
[TBL] [Abstract][Full Text] [Related]
12. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
[TBL] [Abstract][Full Text] [Related]
13. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
14. Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer.
Chen M; Xue J; Sang Y; Jiang W; He W; Hong S; Lv W; Xiao H; Liu R
BMC Cancer; 2023 Apr; 23(1):363. PubMed ID: 37081420
[TBL] [Abstract][Full Text] [Related]
15. Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer.
Ming J; Liu Z; Zeng W; Maimaiti Y; Guo Y; Nie X; Chen C; Zhao X; Shi L; Liu C; Huang T
Int J Clin Exp Pathol; 2015; 8(11):15155-62. PubMed ID: 26823860
[TBL] [Abstract][Full Text] [Related]
16. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of wild-type c-RET and zero prevalence of RET/PTC rearrangements are associated with papillary thyroid cancer (PTC) in Kuwait.
El-Abdallah AA; Junaid TA
Exp Mol Pathol; 2011 Feb; 90(1):61-5. PubMed ID: 20950609
[TBL] [Abstract][Full Text] [Related]
18. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.
Rao PJ; Vardhini NV; Parvathi MV; Murthy PB; Sudhakar G
Tumour Biol; 2014 Oct; 35(10):9539-48. PubMed ID: 24957039
[TBL] [Abstract][Full Text] [Related]
20. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?
Sugg SL; Zheng L; Rosen IB; Freeman JL; Ezzat S; Asa SL
J Clin Endocrinol Metab; 1996 Sep; 81(9):3360-5. PubMed ID: 8784097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
